Key Shin is Of Counsel in the San Francisco office of Morrison & Foerster LLP where he is a member of the Business Department’s Technology Transactions Group. Mr. Shin represents start-ups as well as more established clients in the life sciences and high tech sectors. He advises biotech and pharmaceutical drug development companies as well as medical device and diagnostic companies in planning, negotiating, and executing transactions that advance the development and commercialization of novel technologies and associated intellectual property (IP) assets. Types of transactions on which Mr. Shin provides counsel include:

• license, co-development and marketing agreements
• collaborations and alliances for development and commercialization
• clinical trial agreements and associated documentation
• university sponsored research agreements and technology licenses
• asset purchase agreements
• venture financings and mergers and acquisitions

Mr. Shin has been with Morrison & Foerster since 2003. Previously, Mr. Shin served as the Associate General Counsel for Nuvelo, Inc., and practiced technology transactions and corporate commercial law with Brobeck, Phleger & Harrison, LLP, and Borden Ladner Gervais LLP. Mr. Shin received his law degree from the University of Victoria and his B.Sc. in biology from Queen’s University. Mr. Shin is a member of the California State Bar.

Representative Matters

Collaborations and Licenses

• Novadaq Corp. in its acquisition of exclusive United State distribution rights for PLC Medical System’s Hear Laser System for transmyocardial revascularization from Edwards Lifesciences.
• Bradley Pharmaceuticals, Inc., in a license agreement with BioSante Pharmaceuticals for United States marketing rights for Bio-E-Gel transdermal gel estradiol.
• NovaRx Corporation in a transaction with Immune Response Corporation to transfer all of the latter’s development and marketing rights to cancer cell line vaccines in-licensed from the Sidney Kimmel Cancer Center.
• Chiron Corporation in a license agreement with Cubist Pharmaceuticals, Inc., to develop and commercialize Cubicin® (Daptomycin for injection), an antibiotic approved for treatment of complicated skin and skin structure infections caused by gram-positive bacteria, in Europe, Australia, New Zealand, India, and certain Central American, South American, and Middle Eastern countries.
• Strata Pharmaceuticals, Inc., in a collaboration and license agreement with Micrologix Biotech Inc. to develop and commercialize MBI-226, a topical cationic antimicrobial peptide in Phase III clinical development for the treatment of catheter-related infections.
• Dynavax Technologies Corporation in a strategic partnering agreement with UCB Pharma to out-license ragweed and grass allergy immunotherapy programs with an option for the peanut allergy program.
• Neurosystec Corporation in a development and license agreement with DURECT Corporation to develop and commercialize compounds for the treatment of tinnitus and to improve postoperative recovery and tolerance of cochlear implants.
• MediGene, Inc., in a license agreement with the University of Chicago for targeting methodology to increase the efficiency of MediGene’s oncolytic herpes simplex virus therapy under phase I/II development.
• Dynavax Technologies Corporation in license and services agreements to form its Singapore-based subsidiary, Dynavax Asia.
• Nuvelo, Inc. (formerly Hyseq Pharmaceuticals, Inc.) in a collaboration with Amgen Inc. to develop and commercialize Alfimeprase, a novel acting thrombolytic, for the treatment of peripheral arterial occlusion and other cardiovascular indications.
• Saegis Pharmaceuticals, Inc., in a license and development arrangement with Eli Lilly and Company for the clinical development of a compound for the enhancement of cognition.
• InSite Vision Incorporated in a collaboration with Bausch & Lomb Inc. for the development and commercialization of a fourth-generation fluoroquinolone combined with InSite Vision’s proprietary ophthalmic drug delivery technology.
• InSite Vision Incorporated in its distribution license with SIFI (Societa Industria Farmaceutica Italiana) S.p.A. for the manufacturing and distribution of InSite Visions’s OcuGene genetic test for glaucoma in Italy.
• Genelabs Technologies, Inc., in a cross-license arrangement with the University of Iowa Research Foundation to study the impact of the Hepatitis G virus (HGV, also known as GB virus C or GBV-C) on human immunodeficiency virus (HIV) infection.

M&As and Financings

• Inamed Corporation in its $3.4 billion acquisition by Allergan, Inc.
• Applied Biosystems, Inc., in its $120 million acquisition of Agencourt Personal Genomics, a developer of next generation genetic analysis technologies.
• Oculex Pharmaceuticals, Inc., a developer of innovative therapies for sight-threatening diseases, in its $230 million acquisition by Allergan, Inc. Oculex’s lead product Posurdex® showed promising Phase II results for macula edema.
• Applied Biosystems, Inc., in its acquisition of Ambion, Inc., and subsequent spinout of the diagnostics and services business.
• Jennerex Biotherapeutics, Inc., a novel cancer therapeutic company in its Series A financing.
• Pequot Capital Management, Inc., in its lead of the $10.8 million Series B financing of NuGen Technologies, Inc., developer of single primer isothermal nucleic acid amplification and analysis technologies.
• Lehman Brothers Healthcare Venture Partners in its lead of the $34 million Series C financing of Fluidigm, Inc., developer of microfluidics “lab on a chip” technologies.
• NeuroVentures Capital LLC in its financing of Kadmus Pharmaceuticals, Inc., for development and commercialization of proprietary molecules that target critical pathways contributing to pain and other disorders of the nervous system.
• Philips International in its joint venture with Sony Corp. to acquire InterTrust Technologies, Inc., and its proprietary digital rights management technology for $453 million.

Technology Licenses and Clinical Trial Agreements

Represented various clients in technology licenses and clinical trial agreements opposite the following universities and research institutions:

• Stanford University
• Memorial Sloan-Kettering Cancer Center
• University of Pennsylvania
• University of Chicago
• Georgetown University
• MD Anderson Cancer Center
• Brigham and Women’s Hospital
• University of Maryland (Baltimore)
• University of California, San Francisco
• University of California, Davis
• University of California, Los Angeles
• McGill University
• University of British Columbia
• Simon Fraser University
• University of Minnesota
• University of Washington
• Mayo Clinic
• Thomas Jefferson University
• Boston University
• NIH – National Institutes of Health
• Ottawa Health Research Institute